Get the Stockscreener App
14.45
1.69%
0.24
Pre-market:
14.64
0.19
+1.31%
Amylyx Pharmaceuticals Inc stock is traded at $14.45, with a volume of 630.85K.
It is up +1.69% in the last 24 hours and up +5.17% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
See More
Previous Close:
$14.21
Open:
$14.07
24h Volume:
630.85K
Relative Volume:
0.37
Market Cap:
$1.59B
Revenue:
$-249.00K
Net Income/Loss:
$-187.60M
P/E Ratio:
-5.78
EPS:
-2.5
Net Cash Flow:
$-201.88M
1W Performance:
-3.67%
1M Performance:
+5.17%
6M Performance:
+193.70%
1Y Performance:
+174.71%
1-Day Range:
$13.91
$14.64
1-Week Range:
$13.50
$15.24
52-Week Range:
$2.865
$16.96
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Industry
Phone
617-683-0917
Address
43 THORNDIKE STREET, CAMBRIDGE
Compare AMLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
14.45 | 1.56B | -249.00K | -187.60M | -201.88M | -2.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Guggenheim | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| May-30-25 | Initiated | TD Cowen | Buy |
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Camille Bedrosian Sells 6,580 Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock - MarketBeat
Geode Capital Management LLC Acquires 886,252 Shares of Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Top Executive Makes Significant Stock Sale at Amylyx Pharmaceuticals - TipRanks
Transcript : Amylyx Pharmaceuticals, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 04 - marketscreener.com
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? - Yahoo Finance
Can Amylyx Pharmaceuticals Inc. stock sustain revenue growthJuly 2025 Pullbacks & Stepwise Trade Signal Implementation - Newser
Key facts: Amylyx nears phase III trial for Avexitide; Bedrosian to sell shares - TradingView
Amylyx Pharmaceuticals' co-CEO Justin Klee sells $41,103 in shares - MSN
RSI Check: Will Amylyx Pharmaceuticals Inc. stock benefit from sector rotationJuly 2025 Patterns & High Conviction Investment Ideas - moha.gov.vn
HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PR Newswire
How Amylyx Pharmaceuticals Inc. stock trades before earningsPortfolio Update Summary & Low Risk Growth Stock Ideas - moha.gov.vn
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead - AOL.com
Kennondale Capital Management LLC Has $610,000 Stake in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
17,551 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Acquired by ProShare Advisors LLC - MarketBeat
Amylyx Pharmaceuticals Reports Strong Q3 2025 Results - MSN
Amylyx Pharmaceuticals Inc. (AMLX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How sustainable is Amylyx Pharmaceuticals Inc. stock dividend payoutWeekly Trade Analysis & Free Expert Approved Momentum Trade Ideas - newser.com
Is Amylyx Pharmaceuticals Inc. stock positioned for digital transformationWeekly Stock Recap & Consistent Growth Stock Picks - newser.com
Can Amylyx Pharmaceuticals Inc. stock reach $100 price targetJuly 2025 Volume & Real-Time Stock Price Movement Reports - newser.com
Is Amylyx Pharmaceuticals Inc. stock attractive for growth ETFsOil Prices & Weekly Watchlist for Consistent Profits - newser.com
What the charts say about Amylyx Pharmaceuticals Inc. today2025 Year in Review & Stepwise Trade Signal Guides - newser.com
Will Amylyx Pharmaceuticals Inc. stock deliver better than expected guidanceGap Up & Weekly Return Optimization Plans - newser.com
Real time social sentiment graph for Amylyx Pharmaceuticals Inc.2025 Pullback Review & Verified Momentum Watchlists - newser.com
Is Amylyx Pharmaceuticals Inc. stock attractive for long term wealth buildingTrade Volume Report & Capital Protection Trade Alerts - newser.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Real time alert setup for Amylyx Pharmaceuticals Inc. performanceWeekly Gains Summary & Growth Focused Stock Reports - newser.com
Is Amylyx Pharmaceuticals Inc. stock a defensive play in 2025July 2025 Levels & Verified Chart Pattern Trade Signals - newser.com
Trend analysis for Amylyx Pharmaceuticals Inc. this weekTrade Entry Report & Safe Capital Growth Plans - newser.com
What’s the recovery path for long term holders of Amylyx Pharmaceuticals Inc.Layoff News & Smart Allocation Stock Reports - newser.com
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):